A Study To Evaluate Immune Features Of Inflammatory Arthritis As It Correlates With Imbalance Between T-cell Exhaustion And Senescence
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 20-009041
About this study
The purpose of this study is to systematically examine the immunological features between IA-irAE, classic inflammatory arthritis, ICI-controls and HC.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Adults, ≥ 18 years of age.
- For rheumatoid arthritis patients:
- 2010 EULAR/ACR classification criteria of RA.
- For cancer patients on ICI therapy without irAEs, they will be matched to our existing IA-irAE patients by age, sex, cancer types and ICI treatment.
Exclusion Criteria:
- < 18 years of age.
- For rheumatoid arthritis cohort:
- Active infection;
- Any cancer diagnosis;
- Treatment with biologics;
- Active use of high dose (³ 30 mg daily) of prednisone or steroid equivalent;
- Clinical features suggestive of other non-RA rheumatic disease (e.g., psoriatic arthritis, reactive arthritis, ankylosing spondylitis, lupus, Sjogren’s, , etc) or axial spondyloarthropathy.
- For cancer patient control cohort:
- No irAE ≤ 6 months following final ICI treatment.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Hu Zeng, Ph.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available